Cargando…
Ultra-Early Screening of Cognitive Decline Due to Alzheimer’s Pathology
Alzheimer’s pathology can be assessed and defined via Aβ and tau biomarkers. The preclinical period of Alzheimer’s disease is long and lasts several decades. Although effective therapies to block pathological processes of Alzheimer’s disease are still lacking, downward trends in the incidence and pr...
Autor principal: | Wei, Pengxu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216444/ https://www.ncbi.nlm.nih.gov/pubmed/37239094 http://dx.doi.org/10.3390/biomedicines11051423 |
Ejemplares similares
-
Prevention of and Early Intervention for Cognitive Decline Due to Alzheimer’s Disease and Related Disorders
por: Cohen, PhD, Matthew L., et al.
Publicado: (2021) -
Ultra-Early Phase pathologies of Alzheimer’s disease and other neurodegenerative diseases
por: OKAZAWA, Hitoshi
Publicado: (2017) -
Intracellular amyloid hypothesis for ultra‐early phase pathology of Alzheimer's disease
por: Okazawa, Hitoshi
Publicado: (2021) -
Modelling prognostic trajectories of cognitive decline due to Alzheimer's disease
por: Giorgio, Joseph, et al.
Publicado: (2020) -
The Pathology of Rapid Cognitive Decline in Clinically Diagnosed Alzheimer’s Disease
por: Nance, Christin, et al.
Publicado: (2019)